{"filing":{"accession_number":"0000078003-26-000094","cik":"0000078003","ticker":"PFE","company_name":"PFIZER INC","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-04","primary_document":"pfe-20260804.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/78003/000007800326000094/pfe-20260804.htm"},"events":[{"id":23776,"run_id":21503,"accession_number":"0000078003-26-000094","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing Pfizer's second-quarter 2026 financial results, including revenues of $15.0 billion, reported loss per share of $(0.04), and adjusted diluted EPS of $0.77. The filing includes updated full-year 2026 revenue guidance raised by $500 million at the midpoint, along with detailed operational performance metrics and product-level revenue drivers. The press release is furnished as Exhibit 99 and constitutes the primary disclosure under Item 2.02.","company_name":"PFIZER INC","ticker":"PFE","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24105,"accession_number":"0000078003-26-000094","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Pfizer's second-quarter 2026 financial results, including revenues of $15.0 billion, reported loss per share of $(0.04), and adjusted diluted EPS of $0.77. The filing includes updated full-year 2026 revenue guidance raised by $500 million at the midpoint, along with detailed operational performance metrics and product-level revenue drivers. The press release is furnished as Exhibit 99 and constitutes the primary disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:16:19.094558+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24105,"accession_number":"0000078003-26-000094","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Pfizer's second-quarter 2026 financial results, including revenues of $15.0 billion, reported loss per share of $(0.04), and adjusted diluted EPS of $0.77. The filing includes updated full-year 2026 revenue guidance raised by $500 million at the midpoint, along with detailed operational performance metrics and product-level revenue drivers. The press release is furnished as Exhibit 99 and constitutes the primary disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:16:19.094558+00:00","company_name":"PFIZER INC","ticker":"PFE","filing_date":"2026-08-04"}]}